Basilea Pharmaceutica stock
Price history
+52.46% over the period1 year: from CHF 47.75 (November 20, 2025) to CHF 72.80 (November 20, 2026), +52.46%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | CHF 72.80 |
| October 30, 2026 | CHF 70.80 |
| September 30, 2026 | CHF 69.90 |
| August 31, 2026 | CHF 63.50 |
| July 31, 2026 | CHF 51.90 |
| June 30, 2026 | CHF 53.40 |
| May 29, 2026 | CHF 52.10 |
| April 30, 2026 | CHF 54.40 |
| March 31, 2026 | CHF 54.40 |
| February 27, 2026 | CHF 55.20 |
| January 30, 2026 | CHF 54.00 |
| December 30, 2025 | CHF 54.70 |
| November 28, 2025 | CHF 49.05 |
| November 20, 2025 | CHF 47.75 |
At a glance
The company
Swiss biotech company developing and commercializing treatments for severe bacterial and fungal infections
Latest results
Quarter to June 30, 2026 · EPS CHF 2.12 (estimate CHF 3.34)
TickerLandia's take on Basilea Pharmaceutica
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 29 over its last 4 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 18 vs 15 (+23%) in a group of 7.
- Strong point: Market momentum (88/100 in its group). Weak point: Growth (53/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.96% from the 52-week high
Analysts · 4 analysts
Average targetCHF 99.62+36.84% vs. price
Buy 3 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: Basilea Pharmaceutica
Compared with similar companies: very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow25
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 18.1 22 EV/EBITDA 13.3 23 Forward P/E 12.6 13 Price/book 5.55 54 Price/sales 3.64 15 Profitabilityhigh63
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 38.5% 16 ROA 13.7% 91 ROE 39.5% 86 Net margin 21.2% 63 Operating margin 24.2% 61 Earnings stabilityhigh67
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 10.4% 72 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthaverage53
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +16.29% 45 Revenue growth (year over year) +14.50% 37 Earnings growth (year over year) +64.40% 78 Financial strengthhigh61
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.51 23 Current ratio 6.60 80 Interest coverage 15.6 58 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.31 86 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong88
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +9.42% 75 Relative strength (6 months) +24.19% 90 1-year return +52.46% 91 Distance from 200-day average +25.20% 96 Risklow36
How much the price swings.
Metric Value Position in group Beta (1 year) 0.47 24 Volatility (60 days) 31.3% 64 Maximum drawdown (12 months) 16.9% 21
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Basilea Pharmaceutica is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Basilea Pharmaceutica's P/E today is 23.2, below the median of its last 4 fiscal years (29.2; between 7.10 and 44.9 from 2022 to 2025). Basilea Pharmaceutica's P/E (trailing 12 months): 18.1, +23% against the median of a group of 7 similar companies (14.7).
Compared with 7 similar companies
| Metric | Basilea Pharmaceutica | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.1 | Middle | |
| Forward P/E | 12.6 | Low | |
| Operating margin | 24.2% | Middle | |
| ROE | 39.5% | High | |
| Debt/equity | 0.51 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Basilea Pharmaceutica. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 119M
Latest quarter · Q2 2026
Net income
CHF 27.95M
Latest quarter · Q2 2026
Quarterly net margin
23.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 901.05M
- P/E
- 18.1
- EPS
- CHF 4.01
- Volume
- 26.18K
- Daily trading
- €2.73M
How Basilea Pharmaceutica is changing
All resultsRevenue grew 12.7% a year on average over the last 5 years
Operating margin rose from 14.1% to 22.5%
Profits turn into cash: free cash flow equal to 113% of net income
Returns
Basilea Pharmaceutica returns with dividends
CHF 1,000 invested in Basilea Pharmaceutica 5 years ago, on November 22, 2021, would be worth CHF 1,834 today with dividends reinvested: +83.38% in total, +12.91% per year. On price alone it would be CHF 1,834 (+83.38%).
| Period | Basilea Pharmaceutica | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +7.85% | +0.65% | CHF 1,079 |
| 6 months | +35.06% | +8.75% | CHF 1,351 |
| Year to date | +33.09% | +9.83% | CHF 1,331 |
| 1 year | +52.46% | +16.18% | CHF 1,525 |
| 3 years | +102.22% | +35.68% | CHF 2,022 |
| 5 years | +83.38% | +16.48% | CHF 1,834 |
| 10 years | +0.21% | +85.64% | CHF 1,002 |
Over the last 6 months it has done better than 57% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Basilea Pharmaceutica: technical analysis
Basilea Pharmaceutica is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 74.2% below its all-time closing high (CHF 282.25, March 30, 2007).
- Trend
- Upward
- RSI (14 sessions)
- 58
- Between 30 and 70
- vs 200-session average
- +25.20%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 19, 2026
Support and resistance
Price areas where Basilea Pharmaceutica has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 72.80
- SupportCHF 69.93−3.94%3 touches, last on November 6, 2026
- SupportCHF 58.10−20.19%2 touches, last on April 15, 2026
- SupportCHF 56.13−22.91%4 touches, last on July 10, 2026
Volatility and risk
Over the last year it has moved less than the SMI.
- Beta (1 year) vs SMI
- 0.47
- Volatility (60 sessions, annualised)
- 31.3%
- Largest fall in the last year
- −16.92%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Basilea Pharmaceutica: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for Basilea Pharmaceutica has been January: +5.48% on average, positive in 13 years out of 22. The weakest has been March: −1.88% on average, positive in 8 years out of 22. November, the current month, has been positive in 9 years out of 22 (−1.11% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.48% | +8.47% | 13 of 22 |
| February | +0.62% | +4.64% | 14 of 22 |
| March | −1.88% | −1.88% | 8 of 22 |
| April | −0.76% | −2.21% | 9 of 23 |
| May | +2.48% | +1.30% | 13 of 23 |
| June | −1.69% | −0.36% | 11 of 23 |
| July | +1.17% | +1.79% | 13 of 23 |
| August | +0.16% | −0.62% | 10 of 23 |
| September | +1.63% | +0.76% | 13 of 23 |
| October | −1.09% | −3.16% | 9 of 23 |
| November | −1.11% | −1.45% | 9 of 22 |
| December | +2.44% | +1.16% | 13 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Basilea Pharmaceutica and its competitors
Anti-infective medicines are the core of Basilea Pharmaceutica AG's business, which develops and sells treatments for serious bacterial and fungal infections. Its marketed products are Cresemba, an antifungal given intravenously or orally, and Zevtera, a ceftobiprole-based antibiotic used for pneumonia, Staphylococcus aureus bacteremia and skin infections. The pipeline includes fosmanogepix, a broad-spectrum antifungal for mold infections, and ceftibuten-ledaborbactam etzadroxil, an oral antibiotic for complicated urinary tract infections.
- Headquarters
- Allschwil, Switzerland
- Employees
- 200
- Founded
- 2000
- Chief executive
- David Veitch
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
| Pharma MarPHM | $1.1B | 21.3% | 14.7 | −41.56% |
| IdorsiaIDIA | $1.26B | -68.4% | — | −10.26% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
Same industry or related industries, similar size. Compare Basilea Pharmaceutica with its competitors · Full profile
